Joseph W. LaPlume
Net Worth

Last updated:

What is Joseph W. LaPlume net worth?

The estimated net worth of Mr. Joseph W. LaPlume is at least $22,593,340 as of 10 May 2024. He owns shares worth $3,691,574 as insider, has earned $13,251,086 from insider trading and has received compensation worth at least $5,650,680 in Charles River Laboratories International, Inc..

What is the salary of Joseph W. LaPlume?

Mr. Joseph W. LaPlume salary is $941,780 per year as Corporation Executive Vice President of Corporation Devel. & Strategy in Charles River Laboratories International, Inc..

How old is Joseph W. LaPlume?

Mr. Joseph W. LaPlume is 51 years old, born in 1974.

What stocks does Joseph W. LaPlume currently own?

As insider, Mr. Joseph W. LaPlume owns shares in one company:

Company Title Shares Price per share Total value
Charles River Laboratories International, Inc. (CRL) Corporation Executive Vice President of Corporation Devel. & Strategy 23,276 $158.6 $3,691,574

What does Charles River Laboratories International, Inc. do?

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Joseph W. LaPlume insider trading

Charles River Laboratories International, Inc.

Mr. Joseph W. LaPlume has made 25 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,304 units of CRL stock worth $295,969 on 10 May 2024.

The largest trade he's ever made was exercising 15,418 units of CRL stock on 15 May 2020. As of 10 May 2024 he still owns at least 23,276 units of CRL stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 1,304 $226.97 $295,969
Sale
Common Stock 838 $238.93 $200,223
Sale
Common Stock 1,850 $197.73 $365,801
Option
Common Stock 9,128 $144.67 $1,320,548
Option
Stock Options (Right to Buy) 9,128 $144.67 $1,320,548
Sale
Common Stock 2,585 $172.77 $446,610
Sale
Common Stock 6,543 $173.76 $1,136,912
Sale
Common Stock 700 $216.52 $151,564
Sale
Common Stock 345 $190.39 $65,685
Sale
Common Stock 950 $193.02 $183,369
Sale
Common Stock 9 $194.07 $1,747
Option
Stock Options (Right to Buy) 6,409 $109.34 $700,760
Sale
Common Stock 1,106 $224.85 $248,684
Option
Common Stock 6,409 $109.34 $700,760
Sale
Common Stock 1,138 $223.06 $253,837
Sale
Common Stock 4,165 $224.41 $934,684
Sale
Common Stock 534 $216.36 $115,536
Sale
Common Stock 200 $226.13 $45,227
Sale
Common Stock 395 $292.75 $115,636
Option
Stock Options (Right to Buy) 743 $88.05 $65,421
Sale
Common Stock 392 $290.83 $114,007
Sale
Common Stock 4 $290.81 $1,163
Option
Common Stock 743 $88.05 $65,421
Sale
Common Stock 1,143 $291.8 $333,527
Sale
Common Stock 3,700 $403.6 $1,493,324
Sale
Common Stock 8,735 N/A N/A
Sale
Common Stock 8,735 $70.57 $616,394
Option
Common Stock 2,750 $88.05 $242,138
Option
Stock Options (Right to Buy) 2,750 N/A N/A
Option
Common Stock 6,739 $114.02 $768,381
Option
Stock Options (Right to Buy) 6,739 $114.02 $768,381
Option
Stock Options (Right to Buy) 6,739 $114.02 $768,381
Sale
Common Stock 6,739 $250.17 $1,685,869
Sale
Common Stock 350 $174.65 $61,128
Sale
Common Stock 15,418 $168.4 $2,596,453
Option
Common Stock 6,350 $80.88 $513,556
Option
Stock Options (Right to Buy) 6,350 $80.88 $513,556
Sale
Common Stock 12,958 $137.96 $1,787,738
Option
Common Stock 11,588 $86.94 $1,007,461
Option
Stock Options (Right to Buy) 11,588 $86.94 $1,007,461

Charles River Laboratories International key executives

Charles River Laboratories International, Inc. executives and other stock owners filed with the SEC: